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Objectives. By measuring plasma levels of D-dimer, a product of 
fibrin degradation, we sought o investigate whether the applica. 
tion of radiofrequency (RF) energy might activate ndogenous 
thrombotic mechanisms. 
Background. Quantitative determination of D-dimer, a bio- 
chemical marker of thrombus formation and reactive fibrinolysis, 
helps to diagnose activation of the coagulation system. It remains 
controversial whether endocardial lesions produced uring RF 
catheter ablation of arrhythmogenic foci have a thrombogenic 
effect, and the issue of the need for antithrombotic therapy after 
RF ablation is still unresolved. 
Methods. We made serial determinations of plasma D-dimer 
levels by enzyme immunoassay before insertion of catheters, after 
completion of electrophysiologic study (EPS) but before RF 
ablation, immediately after RF ablation and before discharge (at 
48 h) from the hospital in 37 patients undergoing RF ablation (22 
men, 15 women; mean [-SD] age 37 -+ 18 years, range 12 to 74; 
16 ± 16 lesions produced) of accessory (n = 17) or slow (n = 12) 
pathways, atrial (n = 4) or ventricular foci (n = 3) or the 
atrioventricular node (n = 1). D-dimer levels were also measured 
in 26 age-matched control subjects undergoing EPS only. 
Results. In the RF ablation group, the mean D-dimer levels 
increased from a baseline value of 29 --- 28 to 62 -+ 56/tg/liter after 
EPS (p < 0.0001). However, after RF ablation, D-dimer levels 
increased to much higher levels (188 ± 138 pg/liter, p < 0.0001). 
There was no correlation of D-dimer levels with the number of RF 
lesions produced or the duration of the procedure. At 48 h after 
the procedure, D-dimer levels decreased (75 - 67 p.g/liter) but 
still remained significantly elevated compared with baseline val. 
ues (p = 0.0001). There were no significant differences inbaseline 
(25 ± 21/tg/liter) and post-EPS (51 _+ 50 btg/liter) measurements 
between control subjects and patients. During RF ablation, intra- 
venous heparin was given to nine patients who still demonstrated 
high plasma D-dimer levels after RF ablation. 
Conclusions. As reflected by elevated plasma D-dimer levels, 
RF ablation has a thrombogenic effect hat persists through 48 h 
after the procedure. This effect needs to be taken into account 
when considering antithrombotic therapy in patients undergoing 
RF ablation. 
(J Am CoU Cardiol 1996;28:1257-61) 
The use of radiofrequency (RF) ablation has rapidly expanded 
over the past few years, and the method has become standard 
therapy for certain, mostly supraventricular, rhythmias (1- 
10). Potential thrombogenicity of RF lesions has remained an 
issue over the years because of echocardiographic observations 
of endocardiac thrombi and reports of clinical thromboembolic 
events complicating the procedure (11-14). However, there 
have been no systematic efforts to study the thrombogenic 
potential of these endocardial lesions, and recommendations 
are lacking regarding antithrombotic or anticoagulant therapy 
during or after the procedure (3). Information regarding 
activation of the coagulation and fibrinolytic systems can be 
obtained by measurement of a biochemical marker such as 
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D-dimer, a product of fibrin degradation that is mediated by 
plasmin, which provides an index of thrombus formation and 
reactive fibrinolysis (15). Thus, the purpose of the present 
study was to investigate, by measuring plasma D-dimer levels, 
whether the application of RF energy might activate ndoge- 
nous thrombotic mechanisms having important implications 
for the consideration of future antithrombotic measures. 
Methods  
Patients. Over 20 months, 37 consecutive patients under- 
going RF ablation (22 men, 15 women; mean [_+SD] age 37 +-- 
18 years, range 12 to 74) of accessory (n = 17) or slow (n = 12) 
pathways, atrial (n = 4) or ventricular (n = 3) loci or the 
atrioventricular (AV) node (n : 1) were included in the study. 
All patients had symptomatic tachyarrhythmias and were diag- 
nosed as having Wolff-Parkinson-White syndrome (n = 13) or 
arrhythmias related to a concealed accessory pathway (n = 4), 
AV node reentrant tachycardia (n = 12), atrial tachycardia 
(n = 2) or flutter (n = 2), atrial fibrillation (n -- 1) or 
©1996 by the American College of Cardiology 0735-1097/96/$15.00 
Published by Elsevier Science Inc. Pn s0735-1097(96)00324-5 
1258 MANOLIS  ET AL. JACC Vol. 28, No. 5 
RADIOFREQUENCY ABLAT ION AND D-DIMER November 1, 1996:1257-61 
Abbreviations and Acronyms 
AV - atrioventricular 
EPS = electrophysiologic study 
RF  - radiofrequency 
idiopathic ventricular tachycardia (n = 3). Electrophysiologic 
testing and mapping were always part of the ablation proce- 
dure and routinely preceded the production of RF lesions. 
The study also included 26 patients (age-matched control 
subjects) undergoing electrophysiologic study (EPS) without 
RF ablation (16 men, 10 women; mean age 42 -+ 22 years, 
range 13 to 70). All patients gave written informed consent for 
the procedures. 
Electrophysiologic study. Diagnostic EPS was performed 
in the fasting state after all antiarrhythmic agents had been 
discontinued for a period of at least 5 drug-elimination half- 
lives. Routinely, three 6F quadripolar electrode catheters were 
introduced from the femoral vein and positioned under fluo- 
roscopy at the high right atrium, across the tricuspid valve for 
His bundle recording and at the right ventricular apex. A 6F 
quadripolar or a steerable quadripolar catheter was placed in 
the coronary sinus from either the femoral or left subclavian 
vein. Previously described standard recording methods, pro- 
grammed stimulation techniques, protocols and definitions 
were used (1,4-9). During the initial part of diagnostic EPS, 
the electrophysiologic variables, including conduction and 
refractoriness ofthe atrium, AV node, ventricle and accessory 
pathway were determined, the mechanism of inducible ar- 
rhythmias was defined, and the arrhythmia focus was localized. 
Ablation procedure. After the approximate location of the 
arrhythmia focus had been determined during the initial part 
of the procedure, a 7F steerable quadripolar deflectable-tip 
catheter with a 4-ram distal electrode and 2-5-2-mm interelec- 
trode spacing (Mansfield-Webster, or EP Technologies) was 
used for precise mapping and subsequent ablation with deliv- 
ery of RF current. Access to the left heart was obtained using 
the transseptal pproach for ablation of left-sided accessory 
pathways (6) or of left atrial foci and the transaortic technique 
for ablation of left-sided ventricular tachycardia foci. Only 
patients undergoing ablation of a left-sided arrhythmia focus 
received anticoagulation with heparin while the activated 
clotting time was being monitored and maintained ->300 s 
during the procedure. 
The RF current was generated ata frequency of 500 kHz by 
a conventional nd commercially available lectrosurgical unit 
(Osypka 200S) and was delivered between the distal electrode 
and a cutaneous indifferent dispersive pad positioned on the 
posterior thorax. Once the target site was identified, 20 to 50 W 
of RF energy was delivered through the ablation catheter. If
loss of pre-excitation (in case of manifest accessory pathways), 
termination of the tachycardia (in case of concealed accessory 
pathways or atrial or ventricular tachycardias), accelerated 
junctional rhythm (in case of slow pathway ablation in patients 
with AV node tachycardias) or complete heart block (in the 
case of AV node/His bundle ablation) occurred within 5 to 
15 s, RF application was continued for 30 s, otherwise it was 
stopped, and attempts at mapping and ablation were contin- 
ued. If impedance increased uring ablation, RF application 
was interrupted, the catheter was removed and cleaned before 
reinsertion. At 30 min to 1 h after ablation, programmed 
stimulation was performed to confirm the efficacy of ablation. 
All vascular sheaths were removed at the end of the procedure. 
The patients were then monitored for 48 h before discharge 
from the hospital. During this period, serial electrocardio- 
grams were obtained to evaluate for recurring arrhythmia, nd 
echocardiography was performed to determine the presence of 
cardiac omplications, including the presence of endocardiac 
thrombi. Intravenous heparin for those who underwent abla- 
tion in the left heart was continued for 24 h after the ablation 
procedure. 
Blood sample collection and D-dimer assay. Blood sam- 
ples were obtained from venous heaths and introduced into 
tube collectors containing citrate buffer solution or sodium 
citrate solution. One part of the solution was carefully mixed 
with nine parts of venous blood, avoiding the formation of 
foam. Within 1 h it was centrifuged for 10 rain at -3,000 rpm, 
and the supernatant plasma was removed and kept at -20°C 
until the assay was performed. 
Plasma D-dimer levels were determined by a sand- 
wich enzyme immunoassay method (Enzygnost D-Dimer 
micro, Behring, Germany). All measurements were performed 
in duplicate. Hemolytic, lipemic and rheumatoid factor- 
containing plasmas do not interfere with the determination. I  
healthy subjects the reference range is 4 to 78 p~g/liter (median 
12 p,g/liter). The measurement range extends from 10 to 
600/xg/liter. With regard to specificity, the test does not react 
with fibrinogen or non-cross-linked fibrin(ogen) degradation 
products. The intraassay coefficient of variation falls between 
6% to 13%, whereas the interassay coefficient of variation from 
day to day falls between 4% to 18%. 
From each patient undergoing RF ablation, four blood 
samples were taken for D-dimer measurement. Initially, blood 
samples were obtained immediately after insertion of the 
venous heaths and before introduction of the electrode cath- 
eters (baseline measurements). Subsequently, blood samples 
were taken on completion of EPS and mapping, just before 
production of the first RF lesion (post-EPS measurements). 
The third sample was taken after completion of the RF 
procedure (post-RF measurements) and before sheath re- 
moval. At 40 to 48 h later and before discharge from the 
hospital, a fourth blood sample was obtained. 
Plasma D-dimer levels were also determined in 26 patients 
(age-matched control subjects) undergoing EPS without RF 
ablation. In this group of patients, blood samples were simi- 
larly obtained at baseline and on completion of EPS. In a 
smaller number (n = 13) of the control group, a third sample 
was taken at 24 h later (before discharge). 
Patient follow-up and statistics. After discharge from the 
hospital, patients were to be followed up at our arrhythmia 
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Figure l. Plasma D-dimer levels in 37 patients undergoing EPS 
followed by RF ablation and 26 control subjects with EPS alone. 
Predischarge (pre-DC) measurements were obtained at 48 h and were 
available for all patients, whereas those taken at 24 h were available for 
only 13 control subjects. *p = 0.004, **p < 0.0001, ***p = 0.0504, 
****p = 0.0001 versus baseline. 
clinic or by their referring cardiologists every 3 to 6 months for 
the first year and annually thereafter. All patients who had an 
RF ablation procedure received one aspirin (325 rag) tablet 
daily for 3 months. 
Results are expressed as mean value _+ SD. Statistical 
comparisons were performed using analysis of variance with 
Bonferroni correction and paired or unpaired t tests as appro- 
priate for normal distributions and the Friedman and Wil- 
coxon tests for nonnormal distributions. Correlations between 
procedural variables and plasma D-dimer levels were per- 
formed using linear and multiple regression analysis and the 
Spearman rank correlation (Statview 4.01 program). A p value 
<0.05 was considered significant. 
Results 
Procedural data. Thirty-seven patients undergoing RF ab- 
lation and 26 control subjects undergoing EPS alone were 
included in the study. All procedures were successfully com- 
pleted without he occurrence of any complications. Three to 
four catheters were used in the control group and four to five 
in the ablation group. The total duration of RF ablation in the 
37 patients averaged 3.3 _+ 2.1 h, whereas that of EPS in the 26 
control subjects was 2.7 _+ 0.5 h (p = NS). In the RF ablation 
group, the mean number of RF lesions produced was 16 _+ 16. 
Left-sided foci were ablated in nine patients who received 
intravenous heparin during the procedure. 
D-dimer levels in ablation group. In the ablation group of 
the 37 patients, the mean D-dimer level at baseline was 29 _+ 
28 /~g/liter (Fig. 1). After the EPS and before RF ablation, 
D-dimer levels increased to 62 _+ 56 gg/liter (p < 0.0001 by 
paired t test, but p -- NS by analysis of variance). However, 
after RF ablation was completed, D-dimer levels increased to 
very high levels (188 z 138/xg/liter, p < 0.0001). There was no 
correlation of D-dimer levels with number of RF lesions 
produced (r = 0.23, p = NS) or duration of the procedure (r = 
0.31, p = NS), as determined by linear regression analysis. At 
48 h after the procedure and before hospital discharge, 
D-dimer levels decreased significantly (75 _+ 67/xg/liter com- 
pared with peak levels immediately after ablation but still 
remained significantly elevated compared with baseline values 
(p = 0.0001). 
There were no significant differences in baseline and post- 
EPS measurements between patients and control subjects. The 
highest levels of D-dimer (188 + 138 gg/liter) were noted 
immediately after the procedure in patients undergoing RF 
ablation. Among the nine patients receiving heparin, similarly 
high D-dimer levels were observed (178 _+ 150 gg/liter). 
D-dimer levels in control group. In the control group of 26 
patients undergoing EPS without RF ablation, baseline 
D-dimer levels averaged 25 _+ 21 /xg/liter. On completion of 
EPS, D-dimer levels rose to 51 _+ 50 /xg/liter (p = 0.004), 
values imilar to those in the RF ablation group as measured 
after EPS but before RF ablation, even though the duration of 
EPS in the ablation group was shorter (2.0 - 0.5 vs. 2.7 _+ 0.5 h, 
p < 0.05). In a smaller number (n = 13) of control subjects, 
predischarge measurements of D-dimer levels (40 _+ 26 /~g/ 
liter) were available at 24 h after the procedure, having a 
borderline difference from the baseline values (p = 0.0504). 
Postprocedural data and follow-up. Echocardiograms ob- 
tained after the procedure failed to detect any intracardiac 
tbrombi. No patient in the RF ablation or control group had 
any thromboembolic events during the hospital period, nor was 
any thromboembolism reported uring later follow-up among 
the patients who underwent RF ablation. Patients in the latter 
group were maintained on aspirin (325 mg daily) for 3 months 
after the ablation procedure. 
Discussion 
D-dimer levels and RF ablation procedures. The present 
study demonstrates that plasma levels of D-dimer are in- 
creased uring performance of catheter procedures for man- 
aging cardiac arrhythmias, uch as diagnostic EPS and thera- 
peutic RF catheter ablation. Manipulation of catheters during 
the diagnostic part of the procedure (EPS) appeared to be 
responsible for a moderate increase in D-dimer levels (double 
the baseline measurements), but RF ablation itself induced a 
marked increase (greater than sixfold increase above baseline 
values) in the plasma levels of this biochemical marker of 
thrombogenesis. Clearly this was not just the result of a longer 
RF ablation procedure because the control group had cathe- 
ters in place for a similar duration (mean 2.7 vs. 3.3 h, control 
vs. RF group, p -- NS), whereas there was no correlation 
between degree of D-dimer elevation and duration of the 
procedure. Interestingly, D-dimer values were still elevated 
(albeit at lower levels) at 48 h after the procedure (Fig. 1). 
Thromboembolic omplications of RF ablation. Although 
RF catheter ablation has been established as a safe and 
effective technique that offers a cure to patients with a variety 
of symptomatic supraventricular and ventricular tachyarrhyth- 
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mias (1-10), the thromboembolic potential of the procedure 
has long been recognized (11), but only recently have serious 
concerns been raised (13,14). Thromboembolic complications 
have been reported (12-14) both during the perioperative 
period and during follow-up (at 3 months). In this setting, the 
mechanism of thrombogenesis has not been elucidated, but 
endothelial disruption at the site of application of RF current 
might provide the nidus for thrombus formation and subse- 
quent embolization. The results of our study indicate that RF 
ablation activates fibrin generation and lysis to a much greater 
degree than does simple electrode catheter manipulation 
during the diagnostic (EPS) part of the procedure. The degree 
of D-dimer level elevation could not be merely attributed to 
the large number of RF applications or the long duration of 
the procedure because plasma D-dimer levels were not found 
to correlate particularly with either the number of RF appli- 
cations or the duration of the procedure, nor was there any 
influence observed by the administration ofheparin. However, 
the latter observation is good evidence that the tissue injury is 
causing the thrombogenesis rather than the RF heating of 
blood itself despite the observed lack of correlation between 
number of RF applications and D-dimer levels. Apparently, 
the number of RF applications did not correlate with the 
extent of injured myocardial tissue in the present study because 
not all RF applications probably resulted in effective lesion 
formation, either due to unstable catheter position or our 
practice of interrupting unsuccessful RF applications within 5 
to 15 s, or both. Also, the direct effects of heating enerated by 
the RF ener~ on other clotting factors of the coagulation 
cascade, such as fibrinogen, should not be ignored, and future 
studies need to further explore this possibility. 
Antithrombotic measures. The present study does not pro- 
vide data to explain the lack of clinical thromboembolism in 
this group of patients despite (indirect) indexes of intense 
thrombogenesis. Heparin apparently did not provide any pro- 
tection against he specific wpe of thrombogenicity. That some 
embolic events may remain subclinical or unrecognized, espe- 
cially in patients undergoing right-sided procedures (in the 
absence of right to left shunting) can be appreciated. Further- 
more, all our patients received antithrombotic therapy with 
daily aspirin for the apparently critical period of 3 months after 
ablation (12), but whether this measure was protective remains 
highly speculative. Further prospective studies are required to 
specifically address these daunting issues and evaluate specific 
antithrombotic measures. 
Study limitations. The problem of thromboembolism is 
certainly multifaceted and cannot be fully studied with the 
determination ofplasma levels of only one particular biochem- 
ical marker of thrombosis or thrombolysis. Further studies 
assessing a variety of such coagulation markers (15,16) will be 
needed to identify particular aspects of intravascular thrombo- 
philia that appears to be induced by the application of RF 
current to endocardial sites. The present study included a 
heterogeneous cohort in terms of varying underlying arrhyth- 
mia substrates and therefore different approaches to catheter 
ablation. This fact may or may not have any importance in 
leading to a better understanding of the mechanism by which 
thrombogenicity is incurred. Although no relation was found 
between D-dimer elevation and the number of RF applica- 
tions, procedure duration or heparin use, one cannot ex- 
clude that this lack was due to the size of the study sample. 
However, a more plausible explanation for the lack of cor- 
relation between number of RF applications and D-dimer 
levels would be our inability to differentiate between effec- 
tive and ineffective lesions; in future studies, this drawback may 
be circumvented by temperature-guided ablation. Finally, ther- 
apeutic measures, not evaluated in the present study, that 
will prevent activation of thrombosis and minimize the throm- 
boembolic potential of the procedure need to be investigated 
(15). 
Clinical implications. The present study offers a new ap- 
proach to studying activation of the coagulation cascade during 
catheter ablation. It suggests that subclinical thrombosis may 
be ubiquitous after catheter ablation, as evidenced by the 
D-dimer elevation in patients undergoing these procedures. 
Further insight into the mechanism of such thrombogenicity 
needs to be obtained in properly designed studies. Preliminary 
data from our laboratory (17) indicate that certain antithrom- 
botic regimens can mitigate the degree of D-dimer elevation 
and thus confer a lower thrombogenic potential and may be 
worth exploring in future clinical studies. 
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